These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 2185337

  • 1. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma.
    Gianni AM, Bregni M, Siena S, Orazi A, Stern AC, Gandola L, Bonadonna G.
    J Clin Oncol; 1990 May; 8(5):768-78. PubMed ID: 2185337
    [Abstract] [Full Text] [Related]

  • 2. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
    Bregni M, Siena S, Di Nicola M, Dodero A, Peccatori F, Ravagnani F, Danesini G, Laffranchi A, Bonadonna G, Gianni AM.
    J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
    [Abstract] [Full Text] [Related]

  • 3. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
    Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitley M, Frei E, Schnipper LE.
    N Engl J Med; 1988 Sep 08; 319(10):593-8. PubMed ID: 3045544
    [Abstract] [Full Text] [Related]

  • 4. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH, Fay JP, Christiansen NP, Pinero L, Shah D, Stephan M, Herzig GP.
    Clin Cancer Res; 1997 Sep 08; 3(9):1519-26. PubMed ID: 9815838
    [Abstract] [Full Text] [Related]

  • 5. Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma. A pilot study.
    Ho AD, Del Valle F, Engelhard M, Hiddemann W, Rückle H, Schlimok G, Haas R, Thiel E, Andreesen R, Fiedler W.
    Cancer; 1990 Aug 01; 66(3):423-30. PubMed ID: 2194641
    [Abstract] [Full Text] [Related]

  • 6. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
    Ballestrero A, Ferrando F, Garuti A, Basta P, Gonella R, Stura P, Mela GS, Sessarego M, Gobbi M, Patrone F.
    J Clin Oncol; 1999 Apr 01; 17(4):1296. PubMed ID: 10561192
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.
    Gianni AM, Bregni M, Siena S, Magni M, Di Nicola M, Lombardi F, Tarella C, Pileri A, Bonadonna G.
    J Clin Oncol; 1992 Dec 01; 10(12):1955-62. PubMed ID: 1280674
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy.
    Herrmann F, Schulz G, Wieser M, Kolbe K, Nicolay U, Noack M, Lindemann A, Mertelsmann R.
    Am J Med; 1990 Jun 01; 88(6):619-24. PubMed ID: 2189305
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
    O'Shaughnessy JA, Denicoff AM, Venzon DJ, Danforth D, Pierce LJ, Frame JN, Bastian A, Ghosh B, Goldspiel B, Miller L.
    Ann Oncol; 1994 Oct 01; 5(8):709-16. PubMed ID: 7826903
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study.
    Bergmann L, Karakas T, Knuth A, Lautenschläger G, Mitrou PS, Hoelzer D.
    Eur J Cancer; 1995 Dec 01; 31A(13-14):2164-8. PubMed ID: 8652236
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
    Smith GM, Child JA, Cullen MH, Bailey NP, Woodruffe CM, Fletcher J, Earl H, Barnard D.
    Hematol Oncol; 1996 Dec 01; 14(4):193-201. PubMed ID: 9267465
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.